|
A
Nucleoside Analogue-sparing Strategy for Treatment of Chronic HIV
Nucleoside analogue-sparing combinations can serve as beneficial
first-line anti-HIV drug regimens. This infrequently employed treatment
approach spares the nucleoside
analogue reverse transcriptase inhibitor (NRTI) drug class for future use. In addition,
this strategy eliminates any immediate threat of mitochondrial toxicity
though exposure to the NRTIs.
Various
combinations of nucleoside analogue-sparing anti-HIV drug combinations
are theoretically available and potentially useful. For example,
non
nucleoside reverse transcriptase inhibitors (NNRTIs) associated with protease
inhibitor (PI) and boosted double-PI combinations have been used in clinical studies.
The
results of these studies, although small and not comparative, suggest
they are well tolerated, safe and offer potent suppression of HIV.
One drawback of this approach, however, is that the NNRTIs and PIs
are metabolized in the liver through the cytochrome P450 pathway,
which may produce a number of unwanted
drug interactions. In order to use this strategy, physicians must possess extensive
knowledge of the potential interactions between NNRTIs and PIs or
have access to a database on these interactions to assure use of
the correct drug exposures.
In
some instances, avoidance of interactions may result in the use
of such a high pill burden that the regimen becomes impractical.
As well, patients may experience GI side effects that limit the
use of ritonavir-boosted double combination PI regimens.
New
NRTI-sparing combination regimens have emerged: lopinavir/ritonavir (Kaletra)
monotherapy has shown early, for instance promise. Once oral entry
inhibitors become available,
agents from this unique drug class might be used as part of NRTI-sparing
regimens.
03/16/05
Reference
V
Joly and P Yeni. Nucleoside
analogue-sparing strategy for the treatment of chronic HIV infection:
potential interest and clinical experience. Antiviral
Therapy 1: 29–40. 2005.
Link to Index of All HIV and AIDS
Articles by Topic
|